Immucell vs Local Bounti
Local Bounti is the larger business, with $48.4m of revenue in fiscal 2025 against $27.6m for Immucell (1.7 times as much). Local Bounti grew faster (26.8% against 4.3%). Immucell kept more of each dollar of sales as profit: a net margin of -3.8% against -195.1%.
| Latest fiscal year | ImmucellICCC, 2025 | Local BountiLOCL, 2025 |
|---|---|---|
| Revenue | $27.6m | $48.4m |
| Revenue growth | 4.3% | 26.8% |
| Net income | −$1.0m | −$94.4m |
| Operating margin | 6.0% | — |
| Net margin | -3.8% | -195.1% |
| Return on equity | -3.8% | — |
| Free cash flow | $1.2m | −$41.9m |
| Cash | $3.8m | $4.2m |
| Total debt | $9.1m | $483m |
| Debt to equity | 33.6% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 73 | 286 |
| Market value | $95.8m | $21.4m |
| Price vs our value range | Above our value range | — |
| Moat score | 34 (Weak) | 21 (Weak) |
| Insider trades, 12 months | 8 buys, 0 sales | 0 buys, 12 sales |